Evidence map›Paper›PMID 30684217›Full record

ReviewMolecular neurobiology2019

Molecular Insights into NR4A2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death.

Md Jakaria, Md Ezazul Haque, Duk-Yeon Cho, Shofiul Azam, In-Su Kim, Dong-Kug Choi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Regulation ofInternational journal of molecular sciences · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Md JakariaDepartment of Applied Life Sciences and Integrated Bioscience, Graduate School, Konkuk University, Chungju, South Korea.
Md Ezazul HaqueDepartment of Applied Life Sciences and Integrated Bioscience, Graduate School, Konkuk University, Chungju, South Korea.
Duk-Yeon ChoDepartment of Applied Life Sciences and Integrated Bioscience, Graduate School, Konkuk University, Chungju, South Korea.
Shofiul AzamDepartment of Applied Life Sciences and Integrated Bioscience, Graduate School, Konkuk University, Chungju, South Korea.
In-Su KimDepartment of Applied Life Sciences and Integrated Bioscience, Graduate School, Konkuk University, Chungju, South Korea.
Dong-Kug ChoiDepartment of Applied Life Sciences and Integrated Bioscience, Graduate School, Konkuk University, Chungju, South Korea. choidk@kku.ac.kr.ORCID http://orcid.org/0000-0001-7041-1524
Konkuk University · KR

Funding

Ministry of Education, Science, and Technology NRF-2017R1A2A2A07001035
6 · The paper itself

Abstract

NR4A2 is a nuclear receptor and a transcription factor, with distinctive physiological features. In the cell nuclei of the central nervous system, it is widely expressed and identified as a crucial regulator of dopaminergic (DA) neuronal differentiation, survival, and maintenance. Importantly, it has regulated different genes crucial for dopaminergic signals, and its expression has been diminished in both aged and PD post-mortem brains and reduced in PD patients. In microglia and astrocytes, the expression of NR4A2 has been found where it can be capable of inhibiting the expression of proinflammatory mediators; hence, it protected inflammation-mediated DA neuronal death. In addition, NR4A2 plays neuroprotective role via regulating different signals. However, NR4A2 has been mainly focused on Parkinson's research, but, in recent times, it has been studied in Alzheimer's disease (AD), multiple sclerosis (MS), and stroke. Altered expression of NR4A2 is connected to AD progression, and activation of its may improve cognitive function. It is downregulated in peripheral blood mononuclear cells of MS patients; nonetheless, its role in MS has not been fully clear. miR-145-5p known as a putative regulator of NR4A2 and in a middle cerebral artery occlusion/reperfusion model, anti-miR-145-5p administration promoted neurological outcomes in rat. To date, various activators and modulators of NR4A2 have been discovered and investigated as probable therapeutic drugs in neuroinflammatory and neuronal cell death models. The NR4A2 gene and cell-based therapy are described as promising drug candidates for neurodegenerative diseases. Moreover, microRNA might have a crucial role in neurodegeneration via affecting NR4A2 expression. Herein, we present the role of NR4A2 in neuroinflammation and neuronal cell death focusing on neurodegenerative conditions and display NR4A2 as a promising therapeutic target for the therapy of neuroprotection.

Indexed as

AnimalsBrainCell DeathHumansInflammationNeuronsNeuroprotectionNeuroprotective AgentsNuclear Receptor Subfamily 4, Group A, Member 2Neuroprotective AgentsNuclear Receptor Subfamily 4, Group A, Member 2NeuroinflammationNeuronal cell death and neuroprotectionNR4A2Nuclear receptorTherapeutic target

Identifiers

PMID30684217
OpenAlexW2911986583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.